CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 37,656 Shares

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 37,656 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total transaction of $22,593.60. Following the sale, the chief executive officer now directly owns 995,195 shares in the company, valued at $597,117. This trade represents a 3.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

CytomX Therapeutics Price Performance

Shares of CTMX traded up $0.00 during trading hours on Monday, reaching $0.67. 695,281 shares of the company's stock traded hands, compared to its average volume of 2,636,110. CytomX Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $5.85. The business's fifty day simple moving average is $0.76 and its two-hundred day simple moving average is $0.98. The firm has a market capitalization of $53.65 million, a price-to-earnings ratio of 3.94 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. On average, equities research analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Remove Ads

Analyst Ratings Changes

A number of brokerages have commented on CTMX. Wedbush restated an "outperform" rating and issued a $5.00 target price on shares of CytomX Therapeutics in a research note on Friday, March 7th. HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, StockNews.com raised CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday, March 10th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.02.

Hedge Funds Weigh In On CytomX Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTMX. FMR LLC raised its position in CytomX Therapeutics by 17.3% in the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock worth $335,000 after acquiring an additional 41,949 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company's stock worth $948,000 after purchasing an additional 34,032 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $104,000. Miller Financial Services LLC acquired a new stake in CytomX Therapeutics during the fourth quarter valued at approximately $26,000. Finally, Traphagen Investment Advisors LLC acquired a new stake in CytomX Therapeutics during the fourth quarter valued at approximately $31,000. 67.77% of the stock is owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.